Early skeletal muscle loss in adolescent and young adult cancer patients treated with anthracycline chemotherapy.
Savannah Victoria WootenFei WangMichael E RothGuanshu LiuJ Andrew LivingstonBehrang AminiSusan C GilchristMichelle HildebrandtEugenie S KleinermanPublished in: Cancer medicine (2023)
Significant skeletal muscle loss is experienced early during treatment in AYA cancer patients. Reductions in skeletal muscle blood flow may be a key contributing factor to anthracycline doxorubicin induced skeletal muscle loss.